Lipocomb (Ezetimibe, Rosuvastatin Zinc)

Ezetimibe, one of the two active ingredients in Lipocomb, blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter located on the brush border of the small intestine. By inhibiting this transporter, ezetimibe prevents the intestinal absorption of both dietary and biliary cholesterol, thereby decreasing the amount of cholesterol that reaches the liver.

The appropriate dose of Lipocomb is determined by the prescribing healthcare professional based on the patient’s individual clinical condition, baseline lipid levels, and response to therapy. Dosage may be adjusted over time, but specific regimens are not disclosed here and should follow the prescriber’s instructions.

The safety of Lipocomb in pregnancy and lactation has not been established. Because the product contains rosuvastatin, which is classified as contraindicated in pregnancy, and the effects of ezetimibe are also not well defined, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the risk.

To request Lipocomb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lipocomb combines a cholesterol absorption inhibitor (ezetimibe) with a potent HMG‑CoA reductase inhibitor (rosuvastatin zinc), offering additive LDL‑C reduction compared with monotherapy. This dual mechanism can achieve greater lipid lowering than a single statin or ezetimibe alone, while maintaining a convenient single‑tablet regimen.

Lipocomb tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral dosage form.

Lipocomb is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious adverse events linked to Lipocomb include rhabdomyolysis (severe muscle breakdown that can lead to kidney failure), significant liver injury manifested by marked elevations of transaminases or jaundice, and hypersensitivity reactions such as rash, angioedema or anaphylaxis. Patients should seek immediate medical attention if they experience muscle pain, dark urine, severe abdominal discomfort, or signs of an allergic reaction.

Lipocomb is contraindicated in patients with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to ezetimibe, rosuvastatin or any excipients, and in women who are pregnant or may become pregnant. It should also be avoided in individuals taking contraindicated medicines such as strong CYP3A4 inhibitors, cyclosporine, or gemfibrozil without appropriate medical supervision.